Study S001663

A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01212133
Acronym: Lead-In
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 1386
Start: 2010-11
Primary completion: 2012-04
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1114-9324

Registered primary outcomes

The number of serious adverse drug reactions (SADRs) during the study period [during 26 weeks of treatment]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025979	Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India. Wangnoo SK, Indian journal of endocrinology and metabolism	2016	Other trial	PMID 27867889 DOI	registry reference RESULT:27867889